Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland

CONCLUSION: Somatrogon weekly injections were estimated to result in higher NAH, higher QALYs, lower overall costs and lower costs per cm gained than dGHs, in pGHD.PMID:37527156 | DOI:10.1080/13696998.2023.2228167

Source: Journal of Medical Economics - August 1, 2023 Category: Health Management Authors: Simone Rivolo Jane Loftus Balazs Peter Marion Fahey Thitima Kongnakorn Source Type: research